Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors ; volume:36 ; number:10 ; day:13 ; month:8 ; year:2019 ; pages:2638-2678 ; date:10.2019
Advances in therapy ; 36, Heft 10 (13.8.2019), 2638-2678, 10.2019
- Creator
-
Arora, Sanjeevani
Velichinskii, Rodion
Lesh, Randy W.
Ali, Usman
Kubiak, Michal
Bansal, Pranshu
Borghaei, Hossein
Edelman, Martin J.
Boumber, Yanis
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-019-01051-z
- URN
-
urn:nbn:de:101:1-2020021310543234131750
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Arora, Sanjeevani
- Velichinskii, Rodion
- Lesh, Randy W.
- Ali, Usman
- Kubiak, Michal
- Bansal, Pranshu
- Borghaei, Hossein
- Edelman, Martin J.
- Boumber, Yanis
- SpringerLink (Online service)
Other Objects (12)
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors
Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Immunotherapy biomarkers 2016: overcoming the barriers
Samd3 expressing cell contribute critically to checkpoint immunotherapy
Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy
Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
The role of biomarkers in personalized immunotherapy
Advances in predictive biomarkers for melanoma immunotherapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors
Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Immunotherapy biomarkers 2016: overcoming the barriers
Samd3 expressing cell contribute critically to checkpoint immunotherapy
Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy
Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
The role of biomarkers in personalized immunotherapy
Advances in predictive biomarkers for melanoma immunotherapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors
Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Immunotherapy biomarkers 2016: overcoming the barriers
Samd3 expressing cell contribute critically to checkpoint immunotherapy
Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy
Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
The role of biomarkers in personalized immunotherapy
Advances in predictive biomarkers for melanoma immunotherapy